Polymyalgia Rheumatica Not Linked to Increased Mortality
Jul 28, 2025 · In a long-term follow-up study, patients with isolated polymyalgia rheumatica (PMR) and biopsy-confirmed giant cell arteritis (GCA) had no increased all-cause mortality compared …
IV Steroids in GCA: No Visual Benefit, Higher Diabetes Risk
Intravenous methylprednisolone is not significantly beneficial vs oral glucocorticoids in improving visual acuity or survival in patients with giant cell arteritis, and it increases diabetes risk.
Giant Cell Arteritis: An Update on Diagnosis and Management
The long-term therapy and surveillance of patients with GCA is important. The side effects of long-term steroid therapy are protean and must be addressed. All patients need adequate calcium …
Inflammation Often Remains Following Tocilizumab Use for GCA
Feb 3, 2025 · A recent study found that combined tocilizumab and glucocorticoid therapy for at least 6 months did not fully eliminate vascular inflammation in patients with giant cell arteritis.
Tocilizumab Delays: A Barrier in Giant Cell Arteritis Care?
Jul 15, 2025 · Delays in starting tocilizumab therapy for giant cell arteritis are caused partly by delays in insurance approval, and costs vary by insurance type, study finds.
Is It Giant Cell Arteritis? New Tool Can Help - Medscape
Apr 12, 2024 · A new point-of-care prediction tool that uses clinical and ultrasonography findings has good accuracy for identifying giant cell arteritis among patients seen in fast-track clinics. …
FDA Approves Third Tocilizumab Biosimilar - Medscape
Feb 3, 2025 · Avtozma, an anti-interleukin 6 receptor antagonist, is approved for all of the same indications as reference tocilizumab (Actemra) — rheumatoid arthritis (RA), giant cell arteritis ...
Short Steroid Taper Tested With Tocilizumab for GCA - Medscape
Nov 10, 2023 · TOPLINE: A combination of tocilizumab (Actemra) and 8 weeks of tapering prednisone was effective for inducing and maintaining disease remission in adults with giant …
FDA Okays Upadacitinib for Giant Cell Arteritis - Medscape
Apr 29, 2025 · The US Food and Drug Administration (FDA) has approved a new indication for upadacitinib as a treatment for giant cell arteritis (GCA) in adults. This is the first oral JAK …
Giant Cell Arteritis: An Update on Diagnosis and Management
Giant cell arteritis (GCA) is the most common form of vasculitis in the older adult population. A fast diagnosis is important to prevent serious complications.